Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations
Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja M, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, Rauschkolb C, Rice ASC, Sampaio C, Skljarevski V, Sommerville K, Stacey BR, Steigerwald I, Tobias J, Trentacosti AM, Wasan AD, Wells GA, Williams J, Witter J, Ziegler D. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012, 153: 1148-1158. PMID: 22494920, DOI: 10.1016/j.pain.2012.03.003.Peer-Reviewed Original ResearchConceptsRecent randomized clinical trialsClinical trialsAnalgesic treatmentChronic pain clinical trialsPain clinical trialsAnalgesic drug developmentChronic pain treatmentChronic pain trialsRandomized clinical trialsAnalgesic clinical trialsNumber of patientsEvidence-based approachIMMPACT recommendationsPain treatmentPain trialsPharmacologic treatmentAnalgesic trialsPain assessmentAssay sensitivityEfficacious medicationsConsensus meetingNegative trialsImproved efficacyStudy designTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply